ANDA 202268, held by Hospira. Cefepime Hydrochloride.
As of Nov 21, 2026, ANDA 202268 (Cefepime Hydrochloride), held by Hospira, was first approved by FDA on Jul 30, 2012, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 30, 2012 | Original application | Approved |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters